Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis

Clin Chim Acta. 1988 Apr 29;173(3):313-6. doi: 10.1016/0009-8981(88)90019-8.

Abstract

We have studied the pharmacokinetics of desferrioxamine (DFA), ferrioxamine (FeA) and aluminoxamine (AlA) in patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) after 10 mg/kg (15.24 mumol/kg) body weight desferrioxamine (DESFERAL) administration by intramuscular and intraperitoneal routes. The results show an easy exchange of DFA between the plasma and the peritoneal fluid regulated by the relative concentrations of DFA in the two compartments. When the equilibrium is reached, the concentration of DFA are approximately the same in the plasma and the peritoneal fluid.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aluminum / pharmacokinetics*
  • Chelating Agents / pharmacokinetics*
  • Deferoxamine / pharmacokinetics*
  • Humans
  • Iron / pharmacokinetics*
  • Kidney Failure, Chronic / metabolism
  • Kidney Failure, Chronic / therapy
  • Male
  • Peritoneal Dialysis, Continuous Ambulatory*

Substances

  • Chelating Agents
  • Aluminum
  • Iron
  • Deferoxamine